Issue Information.
- Published in:
- Cancer Communications, 2020, v. 40, n. 8, p. 327, doi. 10.1002/cac2.12090
- Publication type:
- Article
Works matching IS 25233548 AND DT 2020 AND VI 40 AND IP 8
Results: 7
1
2
Single‐cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy.
- Published in:
- Cancer Communications, 2020, v. 40, n. 8, p. 329, doi. 10.1002/cac2.12078
- By:
- Publication type:
- Article
3
Clinical outcomes of coronavirus disease 2019 (COVID‐19) in cancer patients with prior exposure to immune checkpoint inhibitors.
- Published in:
- Cancer Communications, 2020, v. 40, n. 8, p. 374, doi. 10.1002/cac2.12077
- By:
- Publication type:
- Article
4
Construction of an integrated prognostic classifier model for predicting the efficacy of immune checkpoint inhibitor therapy in non‐small cell lung cancer.
- Published in:
- Cancer Communications, 2020, v. 40, n. 8, p. 370, doi. 10.1002/cac2.12070
- By:
- Publication type:
- Article
5
Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients.
- Published in:
- Cancer Communications, 2020, v. 40, n. 8, p. 355, doi. 10.1002/cac2.12069
- By:
- Publication type:
- Article
6
A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors.
- Published in:
- Cancer Communications, 2020, v. 40, n. 8, p. 345, doi. 10.1002/cac2.12068
- By:
- Publication type:
- Article
7
Ovarian cancer‐excreted exosomal miR‐199a‐5p suppresses tumor metastasis by targeting hypoxia‐inducible factor‐2α in hypoxia microenvironment.
- Published in:
- Cancer Communications, 2020, v. 40, n. 8, p. 380, doi. 10.1002/cac2.12034
- By:
- Publication type:
- Article